U.S. markets closed

Gelesis Holdings, Inc. (GLS)

NYSE - NYSE Delayed Price. Currency in USD
0.4800+0.1354 (+39.29%)
At close: 04:01PM EST
0.4100 -0.07 (-14.58%)
After hours: 05:06PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.3446
Bid0.3700 x 3200
Ask0.4277 x 2900
Day's Range0.3259 - 0.4821
52 Week Range0.2400 - 12.2300
Avg. Volume155,026
Market Cap35.056M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-10.8620
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gelesis Holdings, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • Business Wire

    Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference

    BOSTON, November 21, 2022--Gelesis Holdings, Inc. (NYSE: GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Research’s virtual Consumer Growth Conference.

  • Business Wire

    Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

    BOSTON, November 18, 2022--Gelesis Holdings Inc. (NYSE: GLS) ("Gelesis" or the "Company") today noted that on November 16, 2022, the Company received a notification letter (the "Notice") from the New York Stock Exchange (the "NYSE") advising that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because its total market capitalization was less than $50 million over a 30 trading-day period and its stockholders’ equity was l

  • Business Wire

    Gelesis Reports Third Quarter 2022 Results

    BOSTON, November 14, 2022--Gelesis Holdings, Inc. (NYSE: GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity is the only FDA-cleared aid for weight management for people with a BMI as low